Dr. Finn is an Assistant Professor of Medicine in the Department of Cardiology at Emory University. He obtained his MD degree from Vanderbilt University in 2000. During this time Dr. Finn also received a Howard Hughes Research Fellowship for Medical Students which he completed in the laboratory of Dr. David Dichek at the University of California at San Francisco. Dr. Finn did his housestaff, clinical cardiology, interventional cardiology and research training at the Massachusetts General Hospital from 2000 to 2007. In 2007 he joined the faculty of Emory University as an Assistant Professor in the Department of Cardiology. He is board certified in internal medicine, cardiovascular disease, and interventional cardiology.
Research in Dr. Finn’s laboratory combines basic research and clinical investigation, focusing on translational research in the area of atherosclerotic coronary artery disease, including mechanisms of disease, treatment, and exposing potential treatment complications. Currently, his research focuses on three major areas: 1) the effect of drug eluting stents on re-endothelialization of stent surfaces, particularly molecular mechanisms of vascular healing after injury; 2) the role of angiogenesis and intraplaque hemorrhage in coronary plaque progression and inflammation; and 3) the pathophysiology of coronary lesion progression in type 2 diabetics. The Finn lab makes use of both animal models and clinical trials to provide insights into mechanisms of disease and treatment which can be translated directly into the care of patients.
As an example of the first area of research, the lab has demonstrated, in both in animals and humans, that drug eluting stents delay the healing process of the arterial wall. As a result patients receiving these devices are predisposed towards late clotting events (i.e. late thrombosis) and therefore should continue to receive anti-platelet therapy for longer periods of time than was initially recommended based on earlier pivotal clinical trials. The Finn lab is now examining differences in healing responses between sirolimus and paclitaxel and the role of drug interaction in delayed healing. These experiments are conducted both in large animal models of stenting (i.e. rabbit) as well as through ex vivo and in vitro analysis. Projects in this area involve collaboration with Dr. Renu Virmani at CVPath for histological analysis.
Trainees working in Dr. Finn’s lab will: (a) gain experience in creating animal models of arterial injury in both the rabbit and the rat, (b) learn how to perform quantitive morphometric and histologic analysis of histologic sections and measurement of growth factors through ex vivo analysis, and (c) learn how to conduct confocal analysis of stented segments. Trainees will also gain experience in tissue culture and basic molecular techniques of western blotting, quantitative PCR, and transfection of siRNA as well as adenovirus. Collaborations include work done with Dr. Virmani, a world renown cardiac pathologist, and Dr. Robert Taylor, and further opportunities are being explored with investigators at Georgia Institute of Technology.
Dr. Finn practices interventional cardiology one day per week in addition to call duties and ½ day per week of cardiology clinic. Dr. Finn believes strongly in the role of the physician-scientist and has a strong commitment to patient care and clinical medicine. As mentioned earlier, one of Dr. Finn’s interests is in vascular stent healing and so he believes his knowledge as a practicing interventional cardiologist compliments this research interests nicely.
Faculty, to update your profile please click here.